Decentralized clinical trials or DCT have become the new norm for the life sciences industry, particularly the clinical trial domain. The introduction of DCT has improved the flexibility of clinical trial research alongside the discovery of the potential for bringing all clinical research stakeholders on a single page. So, DCT will have a formidable impact on shaping up the clinical trial landscape in 2021 in various aspects.
Here in this blog, we have discussed 5 ways in which decentralized trials will change the clinical research space.
The flexibility of the modular framework in the decentralized model
The modular framework in DCT can help patients, sponsors, clinical sites, and other stakeholders in the trial in accessing a wide range of options. So, new clinical research ventures could capitalize on the opportunities for easy configuration and personalization of alternatives for engagement.
Virtual tools will bring patients closer to clinical trials
The decentralized model can also help in resolving concerns of racial discrimination in healthcare alongside improving overall access to clinical trials. The use of technology, especially virtual tools, can help in removing the unnecessary complications of traveling and distance.
Most important of all, the improved integration of technology in the decentralized model can also promote the integration of diversity as a staple in the processes of clinical study protocol design and initial product development.
Research sites can overcome their uncertainties through decentralized solutions
Research sites are most likely to hold apprehension even if the pharma industry sustains the pace of adopting DCT models. However, the better standards of patient care through the use of DCT model in clinical trials can motivate other research sites to follow the same path.
Some of the key highlights include the facility for clinical trial patients to stay at their homes and obtain access to revolutionary new therapies under the supervision of a physician.
Decentralized solutions enable proactive identification of critical symptoms
The data collection efficiency in DCT platforms can help in the proactive identification of indications about the potential adverse events in a clinical trial. The indications, otherwise known as digital biomarkers, can promote better measures for patient care and the integrity of significant clinical trials.
Enables flexible access translates to trial effectiveness for clinical trials
Finally, it is important to look at the flexibility aspect of the DCT model once again as it can promote better access for all stakeholders. Subsequently, improved collaboration among stakeholders can ensure prolific outcomes such as faster patient enrolment and better retention rates.
With multiple benefits associated with decentralized clinical trial solutions, it is important to consider the ideal technology vendors to support clinical trial ventures in bridging the gaps to implementation of DCT model in their operations.
A comparative analysis to understand the value propositions offered is mandatory for rational decision-making rather than being bait to marketing jargon.